• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.2-氯脱氧腺苷(克拉屈滨)诱导人单核细胞来源的树突状细胞凋亡。
Clin Exp Immunol. 2013 Aug;173(2):288-97. doi: 10.1111/cei.12109.
2
Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia.2-氯脱氧腺苷(克拉屈滨)对原代大鼠小胶质细胞的影响。
J Neuroimmune Pharmacol. 2012 Dec;7(4):939-50. doi: 10.1007/s11481-012-9387-7. Epub 2012 Jul 21.
3
2-Chloro-2'-deoxyadenosine-induced apoptosis in T leukemia cells is mediated via a caspase-3-dependent mitochondrial feedback amplification loop.2-氯-2'-脱氧腺苷诱导T白血病细胞凋亡是通过半胱天冬酶-3依赖性线粒体反馈放大环介导的。
Int J Oncol. 2008 Jun;32(6):1325-33. doi: 10.3892/ijo_32_6_1325.
4
Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration Acutely Influences Monocyte Differentiation but Not Microglial Activation.克拉屈滨治疗多发性硬化症可保留随后生成的单核细胞的分化能力,而其给药则急性影响单核细胞分化但不影响小胶质细胞激活。
Front Immunol. 2022 Jun 6;13:678817. doi: 10.3389/fimmu.2022.678817. eCollection 2022.
5
Mechanism of action of pentostatin and cladribine in hairy cell leukemia.喷司他丁和克拉屈滨在毛细胞白血病中的作用机制。
Leuk Lymphoma. 2011 Jun;52 Suppl 2:43-5. doi: 10.3109/10428194.2011.570394. Epub 2011 Apr 4.
6
[Hairy cell leukemia and its treatment with 2-chlorodeoxyadenosine (2-CdA)].[毛细胞白血病及其2-氯脱氧腺苷(2-CdA)治疗]
Acta Haematol Pol. 1995;26(2):139-43.
7
Synthesis and Functional Investigations of Computer Designed Novel Cladribine-Like Compounds for the Treatment of Multiple Sclerosis.新型克拉屈滨类似物的计算机设计、合成及功能研究用于多发性硬化症的治疗。
Arch Pharm (Weinheim). 2017 Nov;350(11). doi: 10.1002/ardp.201700185. Epub 2017 Sep 28.
8
Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine.2-氯-2'-阿拉伯糖基氟-2'-脱氧腺苷的口服抗淋巴细胞活性及诱导细胞凋亡作用
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2970-4. doi: 10.1073/pnas.89.7.2970.
9
[Clinical pharmacology of 2-chlorodeoxyadenosine (Cladribine)].[2-氯脱氧腺苷(克拉屈滨)的临床药理学]
Przegl Lek. 1996;53(8):614-8.
10
Hairy-cell leukaemia as a model for drug development.毛细胞白血病作为药物研发的模型
Best Pract Res Clin Haematol. 2003 Mar;16(1):83-9. doi: 10.1016/s1521-6926(02)00090-7.

引用本文的文献

1
Uptake of environmental halophilic archaea by human dendritic cells.人类树突状细胞对环境嗜盐古菌的摄取。
Sci Rep. 2025 Jul 1;15(1):21912. doi: 10.1038/s41598-025-07365-z.
2
Glatiramer Acetate Modifies the Immune Profiles of Monocyte-Derived Dendritic Cells In Vitro Without Affecting Their Generation.醋酸格拉替雷可在体外改变单核细胞来源的树突状细胞的免疫谱,而不影响其生成。
Int J Mol Sci. 2025 Mar 26;26(7):3013. doi: 10.3390/ijms26073013.
3
Molecular signature associated with cladribine treatment in patients with multiple sclerosis.与多发性硬化症患者 cladribine 治疗相关的分子特征。
Front Immunol. 2023 Jul 25;14:1233546. doi: 10.3389/fimmu.2023.1233546. eCollection 2023.
4
Oral Cladribine Impairs Intermediate, but Not Conventional, Monocyte Transmigration in Multiple Sclerosis Patients across a Model Blood-Brain Barrier.口服克拉屈滨可损害多发性硬化症患者模型血脑屏障中中间但非传统的单核细胞迁移。
Int J Mol Sci. 2023 Mar 30;24(7):6487. doi: 10.3390/ijms24076487.
5
Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?将多发性硬化症免疫疗法用于慢性炎性脱髓鞘性多发性神经病及其他自身免疫性神经病:是未实现的承诺还是有效的策略?
Ther Adv Neurol Disord. 2023 Jan 2;16:17562864221137129. doi: 10.1177/17562864221137129. eCollection 2023.
6
Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis.疾病修饰疗法对树突状细胞的影响及其在多发性硬化症中的免疫治疗潜力探索。
J Neuroinflammation. 2022 Dec 12;19(1):298. doi: 10.1186/s12974-022-02663-z.
7
Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration Acutely Influences Monocyte Differentiation but Not Microglial Activation.克拉屈滨治疗多发性硬化症可保留随后生成的单核细胞的分化能力,而其给药则急性影响单核细胞分化但不影响小胶质细胞激活。
Front Immunol. 2022 Jun 6;13:678817. doi: 10.3389/fimmu.2022.678817. eCollection 2022.
8
Immunomodulatory Effects Associated with Cladribine Treatment.与克拉屈滨治疗相关的免疫调节作用。
Cells. 2021 Dec 10;10(12):3488. doi: 10.3390/cells10123488.
9
Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets. cladribine 片剂治疗多发性硬化症患者的接种机会。
Curr Neuropharmacol. 2022;20(10):1811-1815. doi: 10.2174/1570159X20666211217160451.
10
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.慢性粒单核细胞白血病伴原始细胞转化的诊治与结局。
Curr Hematol Malig Rep. 2021 Oct;16(5):405-417. doi: 10.1007/s11899-021-00643-3. Epub 2021 Sep 9.

本文引用的文献

1
Drug modification of LPS-stimulated human monocyte-derived dendritic cells.脂多糖刺激的人单核细胞衍生树突状细胞的药物修饰
Br J Biomed Sci. 2012;69(3):126-33.
2
Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia.2-氯脱氧腺苷(克拉屈滨)对原代大鼠小胶质细胞的影响。
J Neuroimmune Pharmacol. 2012 Dec;7(4):939-50. doi: 10.1007/s11481-012-9387-7. Epub 2012 Jul 21.
3
The response of human dendritic cells to co-ligation of pattern-recognition receptors.人类树突状细胞对模式识别受体共交联的反应。
Immunol Res. 2012 Apr;52(1-2):20-33. doi: 10.1007/s12026-012-8279-5.
4
The p53 network: cellular and systemic DNA damage responses in aging and cancer.p53 网络:衰老和癌症中的细胞和全身 DNA 损伤反应。
Trends Genet. 2012 Mar;28(3):128-36. doi: 10.1016/j.tig.2011.12.002. Epub 2012 Jan 20.
5
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.CLARITY 研究中用克拉屈滨片治疗的复发缓解型多发性硬化患者的持续疾病活动状态无进展:一项事后和亚组分析。
Lancet Neurol. 2011 Apr;10(4):329-37. doi: 10.1016/S1474-4422(11)70023-0.
6
Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse.未治疗的多发性硬化症复发患者的脑脊液中浆细胞样树突状细胞增多。
J Neuroinflammation. 2011 Jan 7;8(1):2. doi: 10.1186/1742-2094-8-2.
7
Apoptogenic factors released from mitochondria.线粒体释放的凋亡因子。
Biochim Biophys Acta. 2011 Apr;1813(4):546-50. doi: 10.1016/j.bbamcr.2010.08.002. Epub 2010 Aug 14.
8
Immunomodulatory effects of IFN-beta and lovastatin on immunophenotype of monocyte-derived dendritic cells in multiple sclerosis.干扰素-β和洛伐他汀对多发性硬化症患者单核细胞来源树突状细胞免疫表型的免疫调节作用。
Arch Immunol Ther Exp (Warsz). 2010 Aug;58(4):313-9. doi: 10.1007/s00005-010-0084-z. Epub 2010 Jun 6.
9
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.人 CD141+(BDCA-3)+树突状细胞(DCs)代表了一种独特的髓样 DC 亚群,能够交叉呈递坏死细胞抗原。
J Exp Med. 2010 Jun 7;207(6):1247-60. doi: 10.1084/jem.20092140. Epub 2010 May 17.
10
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.一项口服克拉屈滨治疗复发型多发性硬化的安慰剂对照试验。
N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20.

2-氯脱氧腺苷(克拉屈滨)诱导人单核细胞来源的树突状细胞凋亡。

2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.

机构信息

Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.

出版信息

Clin Exp Immunol. 2013 Aug;173(2):288-97. doi: 10.1111/cei.12109.

DOI:10.1111/cei.12109
PMID:23607690
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3722929/
Abstract

2-Chlorodeoxyadenosine (cladribine, CdA) is an immunosuppressive drug that is licensed to treat hairy cell leukaemia, and has been shown recently to have beneficial effects in patients with multiple sclerosis (MS). The therapeutic effects of CdA have been suggested to be mediated partly through its potent toxicity towards lymphocytes. However, the effects of CdA on other immune cells are poorly understood. In the present study, we investigated the effects of CdA on the induction of apoptosis in human monocytes, monocyte-derived immature (ImDC) and mature (mDC) dendritic cells. Treatment of monocytes with CdA strongly induced apoptosis after 24 h, while apoptosis induction in DC was evident after 72 h. Furthermore, CdA treatment strongly induced caspase-3 and caspase-9 in monocytes, whereas activation of caspases was undetected in DC. The mitochondrial membrane potential in DC was reduced significantly after CdA treatment. DNA hypodiploid assessment showed fragmented nuclei in DC after CdA treatment together with activation of p53 protein. These results revealed that CdA induces caspase-independent apoptosis in DC and suggest cell type specific effects of CdA. This mechanism may contribute to the effect of CdA in autoimmune diseases.

摘要

2-氯脱氧腺苷(克拉屈滨,CdA)是一种免疫抑制剂,已获许可用于治疗毛细胞白血病,最近有研究表明它对多发性硬化症(MS)患者有益。CdA 的治疗效果部分是通过其对淋巴细胞的强烈毒性介导的。然而,CdA 对其他免疫细胞的影响尚不清楚。在本研究中,我们研究了 CdA 对人单核细胞、单核细胞衍生的未成熟(ImDC)和成熟(mDC)树突状细胞凋亡诱导的影响。单核细胞用 CdA 处理 24 小时后强烈诱导凋亡,而 DC 中的凋亡诱导在 72 小时后明显。此外,CdA 处理强烈诱导单核细胞中的 caspase-3 和 caspase-9,而 DC 中未检测到 caspase 的激活。CdA 处理后,DC 中的线粒体膜电位显著降低。DNA 亚二倍体评估显示 CdA 处理后 DC 中有核碎片,并激活 p53 蛋白。这些结果表明 CdA 诱导 DC 中的 caspase 非依赖性凋亡,并提示 CdA 具有细胞类型特异性作用。这种机制可能有助于 CdA 在自身免疫性疾病中的作用。